Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin + Checkpoint Inhibitors in Advanced Cancers
NCT02467361Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Aug 2015
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of napabucasin in cancer (3 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Dose-Limiting Toxicities at 6 weeks and Recommended Phase 2 Dose at 6 weeks. Started Aug 2015; status: completed.
02
Drugs
napabucasin
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02467361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02467361.